Influence of the epiretinal membrane on ranibizumab therapy outcomes in patients with diabetic macular edema

Detalhes bibliográficos
Autor(a) principal: Ercalik,Nimet Yesim
Data de Publicação: 2016
Outros Autores: Imamoglu,Serhat, Kumral,Esra Turkseven, Yenerel,Nursal Melda, Bardak,Handan, Bardak,Yavuz
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Arquivos brasileiros de oftalmologia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492016000600373
Resumo: ABSTRACT Purpose: To investigate the influence of the epiretinal membrane (ERM) on intravitreal ranibizumab (IVR) therapy for diabetic macular edema (DME). Methods: This retrospective study included 56 eyes of 48 patients with DME divided into two groups: the DME with ERM (study) and only DME (control) groups. Changes in the central macular thickness (CMT) and best-corrected visual acuity (BCVA) were evaluated. Results: In the study group, although the CMT was significantly reduced following the first injection (p<0.001), BCVA did not improve significantly (p=0.296). However, after the first injection, the control group exhibited both a significant decrease in CMT (p<0.001) and improvement in BCVA (p<0.001). However, the improvement in BCVA in the control group was not significantly different from the outcome of the study group. Conclusions: We observed a negative short-term influence of the ERM on IVR treatment for DME.
id CBO-2_25229163990d8059c45ae8c635d20f58
oai_identifier_str oai:scielo:S0004-27492016000600373
network_acronym_str CBO-2
network_name_str Arquivos brasileiros de oftalmologia (Online)
repository_id_str
spelling Influence of the epiretinal membrane on ranibizumab therapy outcomes in patients with diabetic macular edemaEpiretinal membraneMacular edemadrug therapyRetinopathydiabetic complicationsRanibizumab/therapeutic useABSTRACT Purpose: To investigate the influence of the epiretinal membrane (ERM) on intravitreal ranibizumab (IVR) therapy for diabetic macular edema (DME). Methods: This retrospective study included 56 eyes of 48 patients with DME divided into two groups: the DME with ERM (study) and only DME (control) groups. Changes in the central macular thickness (CMT) and best-corrected visual acuity (BCVA) were evaluated. Results: In the study group, although the CMT was significantly reduced following the first injection (p<0.001), BCVA did not improve significantly (p=0.296). However, after the first injection, the control group exhibited both a significant decrease in CMT (p<0.001) and improvement in BCVA (p<0.001). However, the improvement in BCVA in the control group was not significantly different from the outcome of the study group. Conclusions: We observed a negative short-term influence of the ERM on IVR treatment for DME.Conselho Brasileiro de Oftalmologia2016-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492016000600373Arquivos Brasileiros de Oftalmologia v.79 n.6 2016reponame:Arquivos brasileiros de oftalmologia (Online)instname:Conselho Brasileiro de Oftalmologia (CBO)instacron:CBO10.5935/0004-2749.20160106info:eu-repo/semantics/openAccessErcalik,Nimet YesimImamoglu,SerhatKumral,Esra TurksevenYenerel,Nursal MeldaBardak,HandanBardak,Yavuzeng2016-12-21T00:00:00Zoai:scielo:S0004-27492016000600373Revistahttp://aboonline.org.br/https://old.scielo.br/oai/scielo-oai.phpaboonline@cbo.com.br||abo@cbo.com.br1678-29250004-2749opendoar:2016-12-21T00:00Arquivos brasileiros de oftalmologia (Online) - Conselho Brasileiro de Oftalmologia (CBO)false
dc.title.none.fl_str_mv Influence of the epiretinal membrane on ranibizumab therapy outcomes in patients with diabetic macular edema
title Influence of the epiretinal membrane on ranibizumab therapy outcomes in patients with diabetic macular edema
spellingShingle Influence of the epiretinal membrane on ranibizumab therapy outcomes in patients with diabetic macular edema
Ercalik,Nimet Yesim
Epiretinal membrane
Macular edema
drug therapy
Retinopathy
diabetic complications
Ranibizumab/therapeutic use
title_short Influence of the epiretinal membrane on ranibizumab therapy outcomes in patients with diabetic macular edema
title_full Influence of the epiretinal membrane on ranibizumab therapy outcomes in patients with diabetic macular edema
title_fullStr Influence of the epiretinal membrane on ranibizumab therapy outcomes in patients with diabetic macular edema
title_full_unstemmed Influence of the epiretinal membrane on ranibizumab therapy outcomes in patients with diabetic macular edema
title_sort Influence of the epiretinal membrane on ranibizumab therapy outcomes in patients with diabetic macular edema
author Ercalik,Nimet Yesim
author_facet Ercalik,Nimet Yesim
Imamoglu,Serhat
Kumral,Esra Turkseven
Yenerel,Nursal Melda
Bardak,Handan
Bardak,Yavuz
author_role author
author2 Imamoglu,Serhat
Kumral,Esra Turkseven
Yenerel,Nursal Melda
Bardak,Handan
Bardak,Yavuz
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Ercalik,Nimet Yesim
Imamoglu,Serhat
Kumral,Esra Turkseven
Yenerel,Nursal Melda
Bardak,Handan
Bardak,Yavuz
dc.subject.por.fl_str_mv Epiretinal membrane
Macular edema
drug therapy
Retinopathy
diabetic complications
Ranibizumab/therapeutic use
topic Epiretinal membrane
Macular edema
drug therapy
Retinopathy
diabetic complications
Ranibizumab/therapeutic use
description ABSTRACT Purpose: To investigate the influence of the epiretinal membrane (ERM) on intravitreal ranibizumab (IVR) therapy for diabetic macular edema (DME). Methods: This retrospective study included 56 eyes of 48 patients with DME divided into two groups: the DME with ERM (study) and only DME (control) groups. Changes in the central macular thickness (CMT) and best-corrected visual acuity (BCVA) were evaluated. Results: In the study group, although the CMT was significantly reduced following the first injection (p<0.001), BCVA did not improve significantly (p=0.296). However, after the first injection, the control group exhibited both a significant decrease in CMT (p<0.001) and improvement in BCVA (p<0.001). However, the improvement in BCVA in the control group was not significantly different from the outcome of the study group. Conclusions: We observed a negative short-term influence of the ERM on IVR treatment for DME.
publishDate 2016
dc.date.none.fl_str_mv 2016-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492016000600373
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492016000600373
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.5935/0004-2749.20160106
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Conselho Brasileiro de Oftalmologia
publisher.none.fl_str_mv Conselho Brasileiro de Oftalmologia
dc.source.none.fl_str_mv Arquivos Brasileiros de Oftalmologia v.79 n.6 2016
reponame:Arquivos brasileiros de oftalmologia (Online)
instname:Conselho Brasileiro de Oftalmologia (CBO)
instacron:CBO
instname_str Conselho Brasileiro de Oftalmologia (CBO)
instacron_str CBO
institution CBO
reponame_str Arquivos brasileiros de oftalmologia (Online)
collection Arquivos brasileiros de oftalmologia (Online)
repository.name.fl_str_mv Arquivos brasileiros de oftalmologia (Online) - Conselho Brasileiro de Oftalmologia (CBO)
repository.mail.fl_str_mv aboonline@cbo.com.br||abo@cbo.com.br
_version_ 1754209029084676096

Registros relacionados